- Home
- Equipment
- netherlands
- multiple myeloma
Refine by
Multiple Myeloma Equipment & Supplies Near Netherlands
88 equipment items found
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While ...
Manufactured by:Antengene Corporation Limited based inChangning District, CHINA
Multiple myeloma is caused by the dysregulated proliferation of plasma cells, characterized by the proliferation of monoclonal plasma cells that results in an overabundance of monoclonal immunoglobulin or its fragment (M protein). Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. 1,2 MM primarily ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex. CYAD-211 is ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology - Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
by:Genmab A/S based inCopenhagen V, DENMARK
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.1 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A subcutaneous formulation of ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Elevenostat (JB3-22) is a selective HDAC11 inhibitor with an IC50 of 0.235 µM. Elevenostat can induce apoptosis of multiple myeloma cells and has anti-tumor effect. In addition, Elevenostat inhibits the maturation of mouse ...
by:Starton Therapeutics based inParamus, NEW JERSEY (USA)
STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is in development for new multiple myeloma indications for lenalidomide and achievement of superiority versus oral lenalidomide in maintenance treatment of multiple myeloma. The STAR-LLD delivery system is expected to provide ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 uniquely activates ...
by:Traws Pharma based inNewtown, PENNSYLVANIA (USA)
Beyond metastatic breast cancer, the Company believes that narazaciclib (ON 123300) may also present an innovative approach to treating other cancers including mantle cell lymphoma, multiple myeloma, advanced colorectal cancer, hepatocellular carcinoma and inoperable ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream ...